Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial
Open Access
- 6 June 2011
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 12 (1) , 140
Abstract
Heart failure is a major cause of morbidity and mortality in society. Current medical therapy centres on neurohormonal modulation with angiotensin converting enzyme inhibitors and β-blockers. There is growing evidence for the use of metabolic manipulating agents as adjunctive therapy in patients with heart failure. We aim to determine the effect of perhexiline on cardiac energetics and alterations in substrate utilisation in patients with non-ischaemic dilated cardiomyopathy. A multi-centre, prospective, randomised double-blind, placebo-controlled trial of 50 subjects with non-ischaemic dilated cardiomyopathy recruited from University Hospital Birmingham NHS Foundation Trust and Cardiff and Vale NHS Trust. Baseline investigations include magnetic resonance spectroscopy to assess cardiac energetic status, echocardiography to assess left ventricular function and assessment of symptomatic status. Subjects are then randomised to receive 200 mg perhexiline maleate or placebo daily for 4 weeks with serum drug level monitoring. All baseline investigations will be repeated at the end of the treatment period. A subgroup of patients will undergo invasive investigations with right and left heart catheterisation to calculate respiratory quotient, and mechanical efficiency. The primary endpoint is an improvement in the phosphocreatine to adenosine triphosphate ratio at 4 weeks. Secondary end points are: i) respiratory quotient; ii) mechanical efficiency; iii) change in left ventricular (LV) function. ClinicalTrials.gov: NCT00841139 ISRCTN: ISRCTN2887836Keywords
This publication has 24 references indexed in Scilit:
- Trimetazidine: a meta-analysis of randomised controlled trials in heart failureHeart, 2010
- Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic CardiomyopathyCirculation, 2010
- Reduced Myocardial Creatine Kinase Flux in Human Myocardial InfarctionCirculation, 2009
- Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failureEuropean Heart Journal, 2006
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyJournal of the American Society of Echocardiography, 2005
- Metabolic Modulation With Perhexiline in Chronic Heart FailureCirculation, 2005
- Myocardial Substrate Metabolism in the Normal and Failing HeartPhysiological Reviews, 2005
- MR spectroscopy quantitation: a review of time‐domain methodsNMR in Biomedicine, 2001
- Is the prognosis of heart failure improving?JACC, 2000
- Cardiac energetics1987